Some policymakers have proposed extending the period during which brand-name pharmaceutical manufacturers can sell their products without facing competition from generic drug makers. But new Commonwealth Fund–supported research led by Aaron S. Kesselheim, M.D. (JAMA Internal Medicine, Sept. 11, 2017) calls into question the impact of additional protections intended to spur further investment in new therapeutics, given that brand-name manufacturers already receive 12 to 16 years of market exclusivity, on average.
Study: Market Protections for Brand-Name Drugs Sustain High Prices
